Patients with high-risk or advanced myeloid malignancies have limited effective treatment options. These include high-dose therapy followed by allogeneic hematopoietic cell transplantation (HCT). We report a single-institution, long-term follow-up of 96 patients, median age 50 (range, 20-60) years, who received HLA-matched related HCT between 1992 and 2007. All patients were treated with a uniform preparatory regimen intended to enhance the widely used regimen of BU and CY that included: BU 16.0 mg/kg (days À8 to À5), etoposide 60 mg/kg (day À4), CY 60 mg/kg (day À2) with GVHD prophylaxis of CsA or FK506 and prednisone. Disease status at transplantation was high-risk AML (n ¼ 41), CML in second chronic phase or blast crisis (n ¼ 8), myelofibrosis and myeloproliferative disorders (n ¼ 8), and myelodysplasia (n ¼ 39). Thirty-six percent (n ¼ 35) of patients received BM whereas 64% (n ¼ 61) received G-CSFmobilized PBPC. With a median follow-up of 5.6 years (range, 1.6-14.6 years) actuarial 5-year OS was 32% (95% CI 22-42) and 5-year EFS was 31% (95% CI 21-41). Relapse rate was 24% (95% CI 15-33) at 2 and 5 years. Nonrelapse mortality was 29% (95% CI 20-38) at day 100 and 38% (95% CI 29-47) at 1 year. Cumulative incidence of acute (grade II-IV) and extensive chronic GVHD was 27% (95% CI 18-36) and 29% (95% CI 18-40), respectively. There was no statistically significant difference in OS (31 vs 32%, P ¼ 0.89) or relapse rates (17 vs 28%, P ¼ 0.22) for recipients of BM vs PBPC, respectively. These results confirm that patients with highrisk or advanced myeloid malignancies can achieve longterm survival following myeloablative allogeneic HCT with aggressive conditioning.
Introduction
Patients with high-risk myeloid malignancies including primary induction failure (IF), refractory relapse, or in second or subsequent remission essentially have no chance of cure with standard chemotherapy. Long-term survival is possible in such patients with myeloablative allogeneic hematopoietic cell transplantation (HCT) with diseasefree survival in the range of 10-30% and nonrelapse mortality (NRM) risk of 30-50%. [1] [2] [3] Among the patients with refractory relapsed disease, results are marginally better in those with lower leukemia burden without circulating blasts. 2, 4, 5 These poor expectations have led to the approach of administering intensive chemotherapy before transplantation in an attempt to reduce the tumor burden. Whether these attempts at reducing tumor burden change the ultimate outcome of transplantation remains unknown. Earlier attempts to increase intensity of fully ablative regimens to improve disease eradication have been associated with increased toxicity and NRM. In addition, TBI-based regimens are associated with notable NRM and toxicity especially in older patients and are generally not used in patients more than 50-55 years of age. 6 Historically, phase I/II studies evaluating the safety and antileukemic activity of including VP-16 in a myeloablative transplant regimen showed promising results. A randomized study carried out under the auspices of Southwest Oncology Group compared two full-dose transplant regimens, fractionated TBI/etopside to BU-CY, and showed similar toxicity, incidence of acute GVHD, OS and diseasefree survival. 7 The combination of BU, CY and etoposide as conditioning regimen was explored for AML patients in first CR and was found to be highly effective regimen with reduced relapsed rates, justifying its use in AML patients who have an HLA-identical donor. 8 However, conditioning with 30 mg/kg rather than 45 mg/kg etoposide resulted in less toxicity and a better OS because of a lower TRM in a recent report. 9 In our study, we used higher dose of etoposide at 60 mg/kg, which was maximally tolerated dose in phase I/II studies. We now report on the long-term follow-up of patients transplanted using BU, etoposide and CY as an aggressive conditioning regimen in a relatively uniform group of patients with high-risk myeloid malignancies with a matched sibling donor as the source of hematopoietic progenitor cells.
Patients and methods

Patients
During the period between December 1992 and January 2007, a total of 96 consecutive patients and their donors provided informed consent and were enrolled in this transplant protocol approved by the Stanford University Institutional Review Board. Censoring date was the last clinic visit before 1 January 2008 allowing for a minimum follow-up of 12 months. Disease status at the start of conditioning was assigned according to consensus guidelines. These patients represented a group of high-risk patients defined as: AML patients X50 years of age in CR1 with high-risk cytogenetics; 10 in CR2 or beyond, with refractory disease, in relapse or with antecedent myelodysplasia (MDS) or myeloproliferative disease (MPD); MDS patients aged 18-60 years; MPD patients aged 18-60 years including CML beyond second chronic phase or blast crisis and myelofibrosis.
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All patients received BM or G-CSF-mobilized PBPC grafts from HLA-matched sibling donors. Thirty-six percent (n ¼ 35) of patients received BM whereas 64% (n ¼ 61) received G-CSF-mobilized PBPC. No graft was manipulated. All 96 patients were included in the analysis. The disease characteristics as well as cytogenetic risk groups for all patients and International Prognostic Scoring System (IPSS) 11 scores for the MDS patients are summarized in Table 1 .
Younger patients with relapsed or refractory acute leukemia received alternate FTBI-based regimens. Exclusion criteria were (1) hepatic dysfunction that was defined by a serum transaminase level 42.5 times the normal value, (2) serum creatinine level 42 mg/100 mL or creatinine clearance o60 mL/min, (3) major organ dysfunction that might increase the risk of the transplantation procedure or (4) severe psychological or medical illness.
Collection of allogeneic hematopoietic cells
The patients were required to have a fully HLA-matched sibling donor. HLA compatibility was initially determined by serological typing and more recently with both serological methods for HLA class I antigens and at least low-resolution molecular typing for HLA class II antigens. BM harvest was performed under anesthesia from the BM donors.
12 HLA-matched PBPC donors received G-CSF at a dose of 16 g/kg per day s.c. beginning on day À5. On day À1, the first apheresis collection began in the afternoon for a 3-to 4-h apheresis procedure. The goal was 5 Â 10 6 CD34 cells per kg of recipient weight. If this goal was not achieved in the first apheresis procedure, a second apheresis was performed on the morning of day 0. A minimum dose of 3 Â 10 6 CD34 cells per kg of recipient weight was required for the allografting. The hematopoietic cell products were not manipulated except for RBC depletion in the case of a major blood group mismatch between donor and recipient. 
GVHD prophylaxis and therapy
CsA or tacrolimus (i.v.) in combination with corticosteroids were used for GVHD prophylaxis. CsA (3 mg/kg per day) or tacrolimus (0.03 mg/kg per day) was begun by continuous infusion on day -1, targeting serum trough levels between 200 and 400 mg/100 mL for CsA or 5 and 15 ng/mL for tacrolimus until day þ 90 with subsequent taper. Patients received methylprednisolone at 0.5 mg/kg, two times a day from day þ 7 to day þ 28. Beginning on day þ 29, corticosteroid doses of all patients were reduced to 0.4 mg/kg two times a day with progressive taper over the next 36 months. Tapering of immunosuppression was stopped in the setting of a GVHD diagnosis. Patients were administered oral CsA or tacrolimus and oral prednisone once their energy intake was adequate.
Supportive care
All patients were housed in private rooms with HEPA filtration systems. Gut decontamination was attempted with nonabsorbable oral antibiotic ciprofloxacin. 13 Pneumocystis carinii (P. jiroveci) prophylaxis was instituted at the beginning of the preparatory regimen with trimethoprim/sulfamethoxazole for 4 days and reinstituted on day 42 through discontinuation of immunosuppressive drugs. Patients received prophylactic acyclovir 5 mg/kg if the they were tested positive for herpes simplex virus beginning on day À1. Until 1998, all patients received low-dose amphotericin B from day þ 1 to day þ 100. From March 1998, antifungal prophylaxis was changed from amphotericin to fluconazole 400 mg q. For patients without evidence of CMV disease in whom CMV viremia resolved during the first 3 weeks, we administered ganciclovir at 5 mg/kg daily for an additional week. In patients with CMV disease or in whom viremia persisted, daily ganciclovir was administered for an additional 4 weeks.
14 Before 1998, the patients had CMV monitoring by qualitative PCR and or surveillance bronchoscopy on day 35 post transplant. All blood products were radiated with 2500 cGy and CMV-negative blood products were used for patients who were seronegative for CMV. Before November 2002, patients received low-dose heparin (100 U/kg per day) by continuous infusion for prevention of hepatic sinusoidal obstructive syndrome (SOS) and continued until WBC engraftment. Subsequent to November 2002, patients received 6 mg/kg per day ursodeoxycholic acid as hepatic SOS prophylaxis until day 90. The patients were monitored for regimen-related toxicities and SOS according to previously reported criteria. 15 HLA and ABO compatibility All 96 patients received HCT from HLA-identical sibling donors with 39 donor-recipient pairs ABO mismatched. A total of 43 patients were sex-matched donors (18 F, 25 M). The remaining patients had donor sex-mismatch with 28 female recipients with male donors and 25 male recipients with female donors.
Cytogenetics
Cytogenetic data were available in all 96 patients as shown in Table 1 . High-risk karyotypes (that is, chromosome 7 deletions or multiple abnormalities) were observed in 33% of patients. AML cytogenetic abnormalities were grouped according to published criteria adopted by the Southwest Oncology Group. 10 Cytogenetic subgroups for MDS were defined as follows: 'favorable risk' group was normal, -Y alone, del (5q) alone, del (20q) alone; 'poor risk' group was complex (43 abnormalities) or chromosome 7 anomalies and 'intermediate risk' group was other abnormalities.
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Definitions Engraftment was defined as the first of 3 consecutive days with an ANC 40.5 Â 10 9 per liter. Failure to engraft by day þ 30 was considered primary graft failure. Platelet engraftment was defined as the first of 7 consecutive days during which the platelet count exceeded 20 Â 10 9 per liter without transfusion support. Acute GVHD and chronic GVHD were graded according to previously described criteria. 16 Chronic GVHD was analyzed in patients who had neutrophil recovery and who survived for more than 90 days and was graded as absent, limited or extensive. 17, 18 NRM was analyzed by day 100 (early NRM) and by 1 year after transplantation (late NRM). Relapsed and refractory disease was defined by morphologic and cytogenetic criteria. Patients without clinical evidence of disease or BM involvement with leukemia were defined as being in CR. Patients who did not respond to standard chemotherapy at initial presentation were classified as having IF. OS was measured from the day of transplantation (day 0) until death from any cause, with censoring performed at the date of last contact. All deaths were considered when OS was evaluated. EFS was defined as the time from day 0 until progression of leukemia, relapse or death from any cause. Relapse was defined as evidence of increased leukemic blasts in the BM. Deaths occurring after disease progression were categorized as relapse regardless of the remote cause of death. Chronic GVHD was defined with NIH consensus criteria: [19] [20] [21] (1) progressive: chronic GVHD following unresolved acute GVHD; (2) quiescent: chronic GVHD occurring after a complete resolution of acute GVHD; (3) de novo: chronic GVHD appearing in a patient with no previous acute GVHD, usually occurring during or at the end of CsA tapering (around day 160-180 post transplant).
Statistical methods
The specific baseline variables evaluated included diagnosis, sex, IPSS score, recipient CMV serostatus and source of hematopoietic stem cells. Outcome variables included OS, EFS, relapse (REL), NRM, cause of death, engraftment times, and acute and chronic GVHD. For analyzing OS and EFS, the Kaplan-Meier method was used to estimate probabilities, the two-tailed log-rank test for comparing survival curves and Cox regression for univariate analyses. Cumulative incidence estimates were calculated for REL and GVHD with deaths as competing events. The cumulative incidences of early and late NRM were also reported, with relapse within the respective time period (100 days or 1 year, respectively) as competing events. Tests according to Fine and Gray were used in group comparisons and univariate competing risk regression. The Mann-Whitney test was used to compare times to engraftment, acute and chronic GVHD between the two sources of hematopoietic stem cells. Comparisons of GVHD incidence between patients with or without CMV reactivation were performed using the Fisher's exact test. Both SAS (Cary, NC, USA) and R software applications (University of Auckland, Auckland, New Zealand) were used for all statistical analyses.
Results
Hematopoietic recovery
All patients achieved hematopoietic recovery with donor cells. The median time to WBC engraftment was 11 days in the PBPC group (range, 9-16 days) compared with 11 days in the BM group (range, 7-44 days) P ¼ 0.74. Median time to reach a platelet engraftment was 16.5 days in the PBPC group (range, 11-81 days) compared with 27 days in the BM group (range, 18-85 days; P ¼ 0.0001).
Acute and chronic GVHD The cumulative incidence of acute GVHD (grades II-IV) was 26% (95% CI 17-35) (Figure 1a ) and the median time to its onset was 17 days (range, 8-55 days). Acute GVHD was the most common cause of early NRM, responsible for 11 deaths. All acute-GVHD-related deaths were associated with grade IV disease. The cumulative incidence of grades II-IV acute GVHD was 17% (95% CI 4-30) with BM compared with 31% (95% CI 19-43) with PBPC (P ¼ 0.2).
The cumulative incidence of chronic GVHD (both limited and extensive) (Figure 1b ) was 54% (95% CI 42-66) and extensive chronic GVHD was 29% (95% CI 18-40). Median time to onset of extensive chronic GVHD was 171 days (range, 90-1546 days). The onset of chronic GVHD was progressive in 13 patients, de novo in 23 patients and interrupted in 2 patients. Extensive chronic GVHD was observed in 20% (95% CI 4-36) of those in the BM group compared with 35% (95% CI 20-50) of the PBPC group (P ¼ 0.21). Skin was the most commonly involved organ occurring in 52% (11 of 21) of patients with extensive GVHD.
CMV reactivation
Seventy-five (78%) patients were at risk of CMV infection. CMV reactivation occurred in 60% (45 of 75) of the patients at risk. CMV disease was diagnosed in 13 patients, Myeloablative conditioning: BU, VP-16, CYs S Naik et al pneumonitis in 6 patients, hepatitis in 1 patient and colitis in 6 patients. CMV disease was the cause of death in five patients, all with CMV pneumonitis. Two of these five patients who died of CMV pneumonitis had concomitant acute GVHD. All patients with CMV enteritis or hepatitis survived. The patients who had asymptomatic CMV reactivation were treated successfully with preemptive DHPG. CMV reactivation occurred in (7 of 16) 42% of at-risk patients who developed grades II-IV acute GVHD compared to (20 of 59) 30% of at-risk patients without grade II-IV acute GVHD (P ¼ 0.36).
Tolerability
The NRM was 29% (95% CI 20-38) at 100 days (early NRM) and 38% (95% CI 28-47) at 1 year, with the causes summarized in Table 2 . Acute GVHD was the most significant cause of early NRM. Two patients (2%) died of SOS in the first 100 days. The overall incidence of SOS was 11.5%, without a difference in SOS incidence regardless of the use of low-dose heparin or ursodeoxycholic acid as SOS prophylaxis. Four patients developed diffuse alveolar hemorrhage. Hemorrhagic cystitis occurred in seven patients with documented BK viruria in five patients. One patient with BK-virus-associated cystitis also developed bilateral hydronephrosis requiring bilateral ureteral stents.
Survival
With a median follow-up of 5.6 years (1.6-14.6 years), actuarial 5-year OS was 32% (95% CI 22-42) and the actuarial 5-year EFS was 31% (95% CI 21-41) for all the patients (Figure 2 ). The relapse rate was 20% at 1 year and 24% (95% CI 15-33) at 2 years with no further increase in relapse after 2 years ( Figure 2 ). There was no statistically significant difference in OS (31 vs 32%, P ¼ 0.89) or EFS (31 vs 32%, P ¼ 0.82) for recipients of BM vs PBPC, respectively. The relapse rate at 2 years was 17% (4-30%) for recipients of BM grafts compared with 28% (16-39%) for recipients of PB grafts (P ¼ 0.22). The actuarial 5-year OS, EFS and relapse rates are summarized in Table 3 .
The univariate analyses including variables of age, percentage of BM blasts, cytogenetics and remission status showed that the percentage of BM blasts at the time of transplantation was the only factor influencing the outcome of AML patients. The hazard ratios for OS and EFS (Figure 3 ) for AML patients with o20 or X20% BM blasts were 2.9 (P ¼ 0.005) and 3 (P ¼ 0.004), respectively. Although the hazard ratios for OS and EFS in relapsed or IF patients compared with CR1 patients were 1.9 and 1.9, respectively, they were not statistically significant (HR 1.9 for OS; P ¼ 0.14 and HR 1.9 for EFS; P ¼ 0.15). Outcomes were also similar regardless of age of the patients or cytogenetic complexity. There was no difference in outcome in MDS patients between different cytogenetic risk groups or in MDS patients younger or older than 50 years of age. In addition to the cytogenetic risk group, the IPSS did not correlate with survival in MDS patients.
Discussion
This study was performed to assess the tolerability and efficacy of the myeloablative preparative regimen of BU, etoposide and CY (BUVPCY) in an effort to improve the outcomes of patients with myeloid malignancies at high risk of relapse. In this study, we showed that BUVPCY conditioning regimen for treatment of high-risk hematological malignancies was associated with long-term survival in one third of the patients. 22 The prolonged follow-up of this study supports the conclusion that myeloablative allogeneic blood or marrow transplantation offers the chance for long-term survival in patients with high-risk, advanced hematological malignancies.
Analysis of results from randomized clinical trials comparing different transplant and nontransplant treatment strategies suggests that allogeneic HCT may be a superior treatment modality for patients with AML in high-risk subgroups. 23 With HLA-identical sibling donor transplantation better outcomes are seen in younger patients and with TBI containing preparative regimens. Myeloablative regimens containing combinations of chemotherapeutic drugs, particularly BU/CY were developed to avoid some of the long-term complications of TBI. The comparison of BUCY2 with CY/TBI showed remarkably similar outcomes in AML. 24 The combination of etoposide and TBI was also found to be equally effective to BU/CY in both ALL and AML. 25 New conditioning regimens are continuously explored trying to reduce toxicity while maintaining antileukemic effects. 26 Etoposide was added in our conditioning regimen in an effort to reduce the tumor burden and the relapse rate due to its antileukemic activity while avoiding the higher risk of NRM associated with TBI.
Intensification of high-dose BU/CY using additional agents has been investigated but with few reported comparisons. Farag et al. 27 compared an intensified regimen of etoposide (60 mg/kg), BU (14 mg/kg) and CY (120 mg/kg) (BUCYVP) with BUCY2 in 237 AML patients without significant difference in survival or relapse rates. In this comparison of BUCYVP with BUCY2, better survival was still observed in subgroup of patients transplanted in Table 2 Early and late nonrelapse mortality among all patients receiving matched sibling donor allogeneic SCT with BU/VP-16/CY CR1 and from related donors. The disease status at transplant was the only factor predicting long-term survival similar to results from our study. For more advanced disease, the Farag et al. study showed a trend toward less relapse with BUCYVP but higher cumulative incidence of transplantrelated deaths compared with BUCY2, resulting in similar survival. 27 The BU/VP/CY regimen used by us had a reduced dose of CY at 60 mg/kg, compared with 120 mg/kg in the Farag trial and 200 mg/kg in standard BUCY. The results of our regimen compare favorably to Farag et al. as well as other reports in this high-risk group of patients. 1, 2, 5, 6 In our high-risk patient population, with a median age of 50 years, the early NRM was 29% with a relapse rate of 24% at 2 and 5 years and an EFS of 31% at 5 years.
Univariate analysis in our study showed that the percentage of BM blasts at the time of transplantation was the only factor that influenced the outcome of AML patients without a similar influence noted on the outcome of MDS patients. This discrepancy between AML and MDS may be due to the AML subgroup having been heavily pretreated and with refractory disease. There were also no differences in outcome in MDS patients regarding cytogenetic risk group, IPSS score or age younger or older than 50 years, differing from previously reported studies showing IPSS score predicting relapse and disease-free survival after allogeneic transplantation. 28, 29 Our current study may not have supported previous findings due to the small number of patients in each MDS subgroup, limiting statistical power.
In a meta-analysis of randomized trials of PBPC vs BM in matched related donors, acute and chronic GVHD were more common after transplantation using PBPC than BM, and may be associated with lower rates of malignant relapse. 30 The beneficial effect of GVL has been previously supported by the significant difference in OS in patients developing chronic GVHD. [31] [32] [33] Our outcomes for both acute and chronic GVHD, EFS and OS were similar for patients who received BM compared with PBPC. Despite patients treated in this study had early NRM due to acute GVHD (11 patients, 39% of all causes of early NRM), interestingly, all long-term survivors had some degree of chronic GVHD. The long-term survivors with chronic GVHD maintained their performance status at 70-90% while on immunosuppressive medications.
Patients with advanced myeloid malignancies have high relapse rates after HCT 22, [34] [35] [36] and, therefore, may benefit from cytoreductive treatment offered by aggressive conditioning regimens. Our study results confirm that patients with high-risk or advanced myeloid malignancies can achieve long-term survival following myeloablative allogeneic HCT with this BU, etoposide and CY conditioning regimen. Relapse and acute GVHD, however, remain significant causes of mortality. Strategies to augment graft-vs-tumor reactions and reduce GVHD remain essential for improving long-term outcomes in these high-risk patient populations.
